Xenon Pharmaceuticals Inc XENE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $38.40
- Day Range
- $38.27–39.43
- 52-Week Range
- $27.99–50.99
- Bid/Ask
- $15.34 / $47.00
- Market Cap
- $2.93 Bil
- Volume/Avg
- 151,806 / 377,239
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 259
- Website
- https://www.xenon-pharma.com
Comparables
Valuation
|
Metric
|
XENE
|
AUPH
|
ELYM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.46 | 2.85 | 1.50 |
Price/Sales | — | 5.05 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
XENE
AUPH
ELYM
Financial Strength
|
Metric
|
XENE
|
AUPH
|
ELYM
|
|---|---|---|---|
Quick Ratio | 23.09 | 4.63 | 59.65 |
Current Ratio | 23.27 | 5.33 | 60.41 |
Interest Coverage | — | −11.69 | — |
Quick Ratio
XENE
AUPH
ELYM
Profitability
|
Metric
|
XENE
|
AUPH
|
ELYM
|
|---|---|---|---|
Return on Assets (Normalized) | −19.13% | −2.14% | −45.38% |
Return on Equity (Normalized) | −20.01% | −3.06% | −46.50% |
Return on Invested Capital (Normalized) | −24.47% | −4.73% | −46.38% |
Return on Assets
XENE
AUPH
ELYM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bcbfsvqwt | Pdtm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fwwhffm | Jxngkfh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Swczdhvk | Dvmsfb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dbmsqtjj | Nsmfbb | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jtvrhgwm | Bgrb | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mslvzcml | Lpgh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Flhlgtnh | Wdg | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ndtxypq | Vglk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lvjpvkhf | Ksvmnbs | $13.4 Bil | |||
| Incyte Corp
INCY
| Xzxxnltxk | Yzpqzc | $12.7 Bil |
United States